Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Meritxell Bellet*, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquín Gavilá, Santiago Escrivá-de-Romaní, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Pilar ZamoraVictoria Reyes, María Alcalde, Helena Masanas, Pamela Céliz, Isabel Ruíz, Miguel Gil, Miguel Àngel Seguí, Lorena de la Peña

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículo de revisiónInvestigaciónrevisión exhaustiva

36 Citas (Scopus)

Resumen

Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the ‘First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications’. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.

Idioma originalInglés
PublicaciónTherapeutic Advances in Medical Oncology
Volumen11
DOI
EstadoPublicada - 1 may 2019

Huella

Profundice en los temas de investigación de 'Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication'. En conjunto forman una huella única.

Citar esto